RT Journal Article
SR Electronic
T1 CoSIR: Optimal control of SIR epidemic dynamics by mapping to Lotka-Volterra System
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20211995
DO 10.1101/2020.11.10.20211995
A1 Maheshwari, Harsh
A1 Shetty, Shreyas
A1 Bannur, Nayana
A1 Merugu, Srujana
YR 2021
UL http://medrxiv.org/content/early/2021/10/06/2020.11.10.20211995.abstract
AB Multiple macro-phenomena such as disease epidemics, online information propagation, and economic activity can be well-approximated using simple dynamical systems. Shaping these phenomena with adaptive control of key levers has long been the holy grail of policymakers. In this paper, we focus on optimal control of transmission rate in epidemic systems following the widely applicable SIR dynamics. We first demonstrate that the SIR model with infectious patients and susceptible contacts (i.e., product of transmission rate and susceptible population) interpreted as predators and prey respectively reduces to a Lotka-Volterra (LV) predator-prey model. The modified SIR system (LVSIR) has a stable equilibrium point, an “energy” conservation property, and exhibits bounded cyclic behavior. We exploit this mapping using a control-Lyapunov approach to design a novel adaptive control policy (CoSIR) that nudges the SIR model to the desired equilibrium. Combining CoSIR policy with data-driven estimation of parameters and adjustments for discrete transmission levels yields a control strategy with practical utility. Empirical comparison with periodic lockdowns on simulated and real COVID-19 data demonstrates the efficacy and adaptability of our approach.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialOur work does not involve clinical trialsFunding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No special approvals were required for this work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for our experiments are publicly available. Data sources include, (i)Public Health England COVID-19 data (ii)Covid19india data (iii)The New York Times COVID-19 data https://data.london.gov.uk/dataset/coronavirus--covid-19--cases https://www.covid19india.org/ https://github.com/nytimes/covid-19-data